Price
579.1
-0.19%52W Range
Market Cap
₹6,126.24 Cr
Traded: ₹11.87 Cr (0.19%) 0.0x
Free Float: ₹2,859.12 Cr (0.42% of FF traded)
Volume · 60D trend
2.06 L 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
MTF Exposure Trend
60 sessions · funded amount, % of FF, daily delta
LAX.SH
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| Profit | +5.0% | +14.0% | +23.0% | -- | +55.0% | Accelerating |
| Return | +10.0% | +20.0% | +54.0% | +136.0% | -- | Accelerating |
| Sales | +5.0% | +10.0% | +7.0% | -- | +15.0% | Stable |
| ROE | +11.0% | +9.0% | +10.0% | -- | -- | Stable |
Quarterly Results
Mar 2023
Dec 2022
Sep 2022
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Jun 2026PDF ↗ | Mar 2026PDF ↗ | Dec 2025PDF ↗ | Sep 2025PDF ↗ | Jun 2025PDF ↗ | Mar 2025PDF ↗ | Dec 2024PDF ↗ | Sep 2024PDF ↗ | Jun 2024PDF ↗ | Mar 2024PDF ↗ | Dec 2023PDF ↗ | Sep 2023PDF ↗ | Jun 2023PDF ↗ | Mar 2023 | Dec 2022 | Sep 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 286 | 257 | 218 | 244 | 207 | 198 | 210 | 218 | 184 | 198 | 201 | 212 | 160 | 185 | 206 | 172 |
| Expenses | 209 | 213 | 183 | 201 | 166 | 177 | 181 | 176 | 149 | 170 | 157 | 158 | 135 | 179 | 158 | 148 |
| Operating Profit | 76 | 44 | 35 | 43 | 41 | 21 | 30 | 41 | 34 | 28 | 44 | 54 | 24 | 6 | 48 | 25 |
| OPM % | 27.0% | 17.0% | 16.0% | 18.0% | 20.0% | 11.0% | 14.0% | 19.0% | 19.0% | 14.0% | 22.0% | 26.0% | 15.0% | 3.0% | 23.0% | 14.0% |
| Other Income | 10 | 11 | 16 | 8 | 35 | 12 | 15 | 5 | 4 | -24 | 5 | 13 | 5 | 3 | 6 | 2 |
| Interest | 1 | 2 | 1 | 3 | 5 | 2 | 1 | 4 | 2 | 2 | 2 | 1 | 1 | 5 | 1 | 2 |
| Depreciation | 10 | 9 | 8 | 8 | 8 | 8 | 8 | 7 | 7 | 7 | 7 | 6 | 6 | 5 | 5 | 5 |
| Profit Before Tax | 75 | 45 | 41 | 41 | 63 | 23 | 36 | 36 | 30 | -4 | 40 | 59 | 22 | -1 | 47 | 20 |
| Tax % | 32.0% | 18.0% | 39.0% | 30.0% | 30.0% | 29.0% | 29.0% | 28.0% | 26.0% | 24.0% | 27.0% | 27.0% | 34.0% | -561.0% | 37.0% | 21.0% |
| Net Profit | 51 | 37 | 25 | 29 | 44 | 17 | 26 | 26 | 22 | -5 | 29 | 43 | 14 | 3 | 30 | 16 |
| Exceptional Items | 0 | 0 | -3 | 0 | 0 | 0 | 0 | 0 | 0 | -29 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Rs) | 4.7 | 3.4 | 2.2 | 2.6 | 4.1 | 1.5 | 2.3 | 2.3 | 2.0 | -0.9 | 2.6 | 4.0 | 1.4 | 0.3 | 2.7 | 1.3 |
| Sales Growth (YoY) | 37.6% | 29.8% | 3.7% | 12.3% | 13.0% | -0.1% | 4.8% | 2.7% | 15.1% | 7.2% | -2.4% | 22.9% | -15.4% | -- | -- | -- |
| Sales Growth (QoQ) | -- | 17.9% | -10.7% | 17.9% | 4.5% | -5.7% | -3.7% | 18.5% | -7.1% | -1.5% | -5.2% | 32.5% | -13.5% | -10.2% | 19.8% | -- |
| OP Growth (YoY) | 85.4% | 109.5% | 16.7% | 4.9% | 20.6% | -25.0% | -31.8% | -24.1% | 41.7% | 366.7% | -8.3% | 116.0% | -- | -- | -- | -- |
| OP Growth (QoQ) | 72.7% | 25.7% | -18.6% | 4.9% | 95.2% | -30.0% | -26.8% | 20.6% | 21.4% | -36.4% | -18.5% | 125.0% | 300.0% | -87.5% | 92.0% | -- |
| Profit Growth (YoY) | 16.0% | 129.0% | 4.0% | 12.0% | 108.0% | 34.0% | -14.0% | -43.0% | 41.0% | 248.0% | -1.0% | 205.0% | -43.0% | -83.0% | 148.1% | -34.9% |
| EPS Growth (YoY) | -- | 128.6% | -2.6% | 11.7% | 107.1% | 269.0% | -14.4% | -43.0% | 39.7% | -371.9% | -1.5% | 204.5% | -- | -- | -- | -- |
| EPS Growth (QoQ) | -- | 52.7% | -14.7% | -36.8% | 177.6% | -35.0% | -2.2% | 17.3% | 326.4% | -132.9% | -34.8% | 187.2% | 340.6% | -88.1% | 101.5% | -- |
| OP Margin | -- | 17.1% | 16.1% | 17.6% | 19.8% | 10.6% | 14.3% | 18.8% | 18.5% | 14.1% | 21.9% | 25.5% | 15.0% | 3.2% | 23.3% | 14.5% |
| Net Margin | -- | 14.4% | 11.5% | 11.9% | 21.3% | 8.6% | 12.4% | 11.9% | 12.0% | -2.5% | 14.4% | 20.3% | 8.8% | 1.6% | 14.6% | 9.3% |
| Material Cost % | -- | 44.1% | 46.6% | 48.3% | 44.3% | 50.2% | 54.3% | 52.8% | 46.4% | 48.2% | 51.1% | 47.1% | 52.9% | 59.0% | 49.3% | 55.5% |
| Employee Cost % | -- | 14.1% | 16.5% | 13.7% | 14.9% | 14.3% | 14.1% | 12.6% | 14.4% | 12.4% | 12.1% | 11.0% | 14.7% | 12.2% | 10.8% | 12.2% |
| P/S | 6.10 | 5.59 | 3.34 | 2.61 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/E | 45.03 | 40.06 | 26.51 | 20.41 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/B | 5.14 | 4.34 | 2.56 | 1.98 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Exchange Filings
50Please find enclosed herewith the Newspaper Publication regarding the publication of the advertisement for the Postal Ballot Notice.
Please find enclosed herewith the Postal Ballot Notice ("Notice") dated August 12, 2026, alongwith the Explanatory Statement for seeking approval of Members of the Company by way of remote ....
Please find enclosed herewith the copies of newspaper advertisement published regarding the extract of statement of Un-audited Standalone and Consolidated Financial Results of the Company ....
Please find enclosed herewith the outcome of Members of the Nomination and Remuneration Committee of Bliss GVS Pharma Limited ("the Company")in its meeting held today i.e. on August 12, ....
We wish to inform you that the Board Meeting of the Company was held today i.e. on Wednesday, August 12, 2026 through Video Conferencing ("VC") / Other Audio Visual Means ("OAVM") with ....
We wish to inform you that the Board Meeting of the Company was held today i.e. on Wednesday, August 12, 2026, through Video Conferencing ("VC")/Other Audio-Visual Means ("OAVM"), with ....
We would like to inform you that the ESOP Allotment Committee of the Company at its meeting held today i.e. August 11, 2026 has approved the allotment of 31, 250 equity shares of the face ....
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Life Insurance Corporation of India
Bliss GVS Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2026 ,inter alia, to consider and approve Pursuant to Regulation 29 ....
SBI Capital Markets Ltd ("Manager to the Open Offer") has submitted to BSE a copy of Pre-Offer Advertisement in accordance with Regulation 18(7) of the Securities and Exchange Board of ....
Please find attached detailed intimation regarding resignation of Mr. Sachin Saboo, Senior Management Personnel of the Company, pursuant to Regulation 30 of SEBI (Listing Obligations and ....
Please find enclosed herewith the Notice sent to shareholders w.r.t. the transfer of Unclaimed Final Dividend 2018-2019 and its corresponding shares to the IEPF Authority.
Please find attached copies of the newspaper publications containing recommendation of the Committee of Independent Directors.
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Clarus Capital I & Others
Please find enclosed herewith the Newspaper publication regarding Notice to Shareholders for Transfer of Unclaimed Final Dividend 2018-2019 and its corresponding Equity Shares to IEPF.
Please find attached the intimation of recommendations by the Committee of Independent Directors pursuant to Regulation 26(7) of the SEBI (Substantial Acquisition of Shares and Takeovers) ....
Letter of Offer dated July 18, 2026 received from SBI Capital Markets Limited, the manager to the Open Offer appointed by Anupam Rasayan India Limited along with PAC.
Addendum to Public Announcement and Detailed Public Statement for the Open Offer made by Anupam Rasayan Limited, the acquirer for the addition of PAC.
Please find enclosed herewith the details of KMPs for reporting Disclosure of Material Events to Stock Exchanges.
Please find attached herewith the proceedings of 41st Annual General Meeting of Bliss GVS Pharma Limited.
Please find enclosed herewith the Voting Results alongwith the Scrutinizer Report for the 41st Annual General Meeting of the Company held on Wednesday, July 15, 2026.
We like to inform you that the ESOP Allotment Committee of the Company at its meeting held today i.e. July 07, 2026 has approved the allotment of 1,87,750 equity shares of the face value ....
Enclosed herewith is the intimation regarding the Change in Management of the Company.
Please find enclosed herewith the Certificate under Regulation 74(5) of the SEBI (D&P) Regulations 2018, for the quarter ended June 30, 2026.
Pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that based on the recommendation ....
Please find enclosed herewith the Intimation regarding the closure of the Trading Window for the quarter ended June 30, 2026.
Please find enclosed herewith the Newspaper Advertisement published regarding Notice of 41st Annual General Meeting, E-voting and Book Closure Information.
Pursuant to Regulation 34(1) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (''SEBI Listing Regulations''), please find ....
Please find enclosed herewith the Notice of 41st AGM of Bliss GVS Pharma Limited ("the Company") scheduled to be held on Wednesday, July 15, 2026, at 11:00 A.M. (IST) through VC/OAVM. The ....
Please find enclosed herewith the intimation for the Book Closure for the purpose of 41st Annual General Meeting of the Company.
Please find enclosed herewith the intimation regarding the Fixation of the record date for the payment of the final dividend for the financial year ended March 31, 2026.
Please find enclosed herewith the Newspaper publication regarding the 41st Annual General Meeting of the Company.
Please find enclosed herewith the communication sent to shareholders regarding Intimation of Tax Deduction on Dividend.
We would like to inform you that the ESOP Allotment Committee at its meeting held today i.e. June 11, 2026 has approved the allotment of 267250 equity shares of face value Re.1/- each to ....
Please find attached a copy of the Draft Letter of Offer (DLOF) from SBI Capital Markets Limited, the Manager to the Open Offer.
SBI Capital Markets Ltd ("Manager to the Open Offer") has submitted to BSE a copy of Draft Letter of Offer to the Public Shareholders of Bliss GVS Pharma Ltd ("Target Company").
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Gagan Harsh Sharma & PACs
Please find attached an intimation of WHO-GMP compliance of manufacturing facility located at Survey No. 43 & 44, Vevoor Village, Palghar (East).
Please find attached a copy of newspaper publication regarding the Detailed Public Statement in connection with the Open Offer made to the public shareholders of the Company.
SBI Capital Markets Ltd ("Manager to the Open Offer") has submitted to BSE a copy of Detailed Public Statement in terms of Regulation 3(1) and Regulation 4 read with Regulation 13(4), Regulation ....
Please find enclosed herewith the Annual Secretarial Compliance Report for the year ended March 31, 2026.
SBI Capital Markets Limited ("Manager to the Offer") has submitted to BSE a copy of Public Announcement for the attention of the Public Shareholders of Bliss GVS Pharma Ltd under Regulation ....
Intimation of Completion of Term of Mr. Santosh Parab (DIN: 01622988) as an Independent Director of the Company.
Please find herewith the Public Announcement in relation to Open Offer to public shareholders issued by SBI Capital Markets Limited.
Please find herewith the outcome of Board Meeting held on May 23, 2026
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Punita Sharma & PACs
Please find enclosed herewith the newspaper publication regarding the publication of Audited Standalone and Consolidated Financial Results of the Company for the quarter and year ended March 31, 2026.
Please find enclosed herewith the Scrutinizer''s Report of Postal Ballot alongwith Voting Results.
Please find enclosed herewith the Disclosure of Voting Results of the Postal Ballot along with Scrutinizer Report.
We would like to inform you that the Board Meeting of the Company was held today i.e. on Tuesday, May 12, 2026, at the registered office of the Company. In pursuance of Regulation 30 and ....
Annual Reports
15Credit Ratings
6Held by ETFs
1 ETFs hold blissgvs · sorted by weight
Held by Mutual Funds
2 schemes hold blissgvs · sorted by weight